What's in VA Office of Research and Development's pipeline?

VA Office of Research and Development has 71 drugs in our index: 36 marketed, 0 filed, 10 in Phase 3, 16 in Phase 2, 8 in Phase 1.

Which companies overlap with VA Office of Research and Development's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, GlaxoSmithKline, University of Pennsylvania, Johns Hopkins University, AstraZeneca.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/va-office-of-research-and-development.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

VA Office of Research and Development — Portfolio Competitive Intelligence Brief

VA Office of Research and Development pipeline: 36 marketed, 0 filed, 10 Phase 3, 16 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

36 marketed 0 filed 10 Phase 3 16 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Nasal Povidone Iodine	Nasal Povidone Iodine	marketed
hydrocodone/APAP w placebo PRN	hydrocodone/APAP w placebo PRN	marketed	Opioid analgesic combination	Mu opioid receptor (hydrocodone); cyclooxygenase enzymes (acetaminophen)	Pain Management
Diuretic initiation or augmentation	Diuretic initiation or augmentation	marketed
Cessation-Phase Varenicline	Cessation-Phase Varenicline	marketed
Topical Chlorhexidine, 4%	Topical Chlorhexidine, 4%	marketed
Open Label (OL) Paroxetine	Open Label (OL) Paroxetine	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)	Psychiatry / Neurology
Sublingual buprenorphine with naloxone	Sublingual buprenorphine with naloxone	marketed
Pluvicto	Pluvicto	marketed		Prostate-specific antigen	Oncology
hydrocodone/APAP	hydrocodone/APAP	marketed	Opioid analgesic combination	Mu opioid receptor (hydrocodone); COX inhibitor (acetaminophen)	Pain Management
TDAP	TDAP	marketed			Other
Blinded clopidogrel	Blinded clopidogrel	marketed	Antiplatelet agents	P2Y12 receptor	Metabolic
Mupirocin calcium ointment, 2%	Mupirocin calcium ointment, 2%	marketed

Therapeutic area mix

Cardiovascular · 5
Pain Management · 4
Other · 3
Gastroenterology · 3
Oncology · 3
Infectious Disease · 2
Hematology · 2
Addiction Medicine / Smoking Cessation · 2
Psychiatry / Mental Health · 2
Psychiatry / Sleep Medicine · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 5 shared drug classes
GlaxoSmithKline · 3 shared drug classes
University of Pennsylvania · 3 shared drug classes
Johns Hopkins University · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Iowa City Veterans Affairs Medical Center · 2 shared drug classes
Abbott · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for VA Office of Research and Development:

Cite this brief

Drug Landscape (2026). VA Office of Research and Development — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/va-office-of-research-and-development. Accessed 2026-05-16.